You are here: Welcome » Valneva VLA2001

Differences

This shows you the differences between two versions of the page.

Link to this comparison view

Both sides previous revisionPrevious revision
Next revision		Previous revision
Both sides next revision
valneva_vla2001 [2021/12/10 18:08]
brian 		valneva_vla2001 [2021/12/10 18:18] (current)
brian
Line 21: Line 21:
  
 |  |   Participants   |   Covid+   |   Total Adverse Events   |   # of Solicited Severe Adverse Events Reported   |    # of Vax Related Serious  Adverse Events  |   Observed AE's   |  |  |   Participants   |   Covid+   |   Total Adverse Events   |   # of Solicited Severe Adverse Events Reported   |    # of Vax Related Serious  Adverse Events  |   Observed AE's   | 
-|Phase1/2|   153   |   2   |   27   |   2   |   0   | pain, tenderness, erythema, induration/swelling, nausea/vomiting, headache, fatigue, myalgia, neutropenia, eosinophilia, thrombocytopenia, chilblains, haematuria, rise in red blood cell/erythrocyte sedimentation rate   |+|Phase1/2|   153   |   2   |   106   |   2   |   0   | pain, tenderness, erythema, induration/swelling, nausea/vomiting, headache, fatigue, myalgia, neutropenia, eosinophilia, thrombocytopenia, chilblains, haematuria, rise in red blood cell/erythrocyte sedimentation rate   |
 |Phase3 |   4,012   |   ?   |   ?   |   0   | |Phase3 |   4,012   |   ?   |   ?   |   0   |
  
 == Published Clinical Trial Results ==  == Published Clinical Trial Results == 
-[[https://www.medrxiv.org/content/10.1101/2021.08.13.21262021v2|Immunogenicity and safety of inactivated whole virion Coronavirus vaccine with CpG (VLA2001) in healthy adults aged 18 to 55: a randomised phase 1 /2 clinical trial]]+[[https://www.medrxiv.org/content/10.1101/2021.08.13.21262021v2|NCT04671017: Immunogenicity and safety of inactivated whole virion Coronavirus vaccine with CpG (VLA2001) in healthy adults aged 18 to 55: a randomised phase 1 /2 clinical trial]]
  
 +{{https://www.medrxiv.org/content/medrxiv/early/2021/08/20/2021.08.13.21262021/T3.medium.gif}}
 +
 +
 +== Registered Clinical Trials ==
   NCT04671017 Dose Finding Study to Evaluate Safety, Tolerability and Immunogenicity of an Inactiviated Adjuvanted Sars-Cov-2 Virus Vaccine Candidate Against Covid-19 in Healthy Adults.    NCT04671017 Dose Finding Study to Evaluate Safety, Tolerability and Immunogenicity of an Inactiviated Adjuvanted Sars-Cov-2 Virus Vaccine Candidate Against Covid-19 in Healthy Adults. 
   NCT04864561 Study To Compare The Immunogenicity Against COVID-19, Of VLA2001 Vaccine To AZD1222 Vaccine (COV-COMPARE).    NCT04864561 Study To Compare The Immunogenicity Against COVID-19, Of VLA2001 Vaccine To AZD1222 Vaccine (COV-COMPARE). 
   NCT04956224 Immunogenicity of VLA2101 Compared to VLA2001.    NCT04956224 Immunogenicity of VLA2101 Compared to VLA2001. 
Back to top